Declan G. Murphy

Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study

Michael S. Hofman, Nathan Lawrentschuk, Roslyn J. Francis et al. · The Lancet · 2020 · 2K citations

Medicine, Nuclear Medicine, Oncology +17

[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study

Michael S. Hofman, John Violet, Rodney J. Hicks et al. · The Lancet Oncology · 2018 · 1.1K citations

Medicine, Nuclear Medicine, Oncology +14

Dosimetry of ¹⁷⁷Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes

John Violet, Price Jackson, Justin Ferdinandus et al. · Journal of Nuclear Medicine · 2018 · 486 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study

Louise Emmett, James P Buteau, Nathan Papa et al. · European Urology · 2021 · 418 citations

Medicine, Oncology, Urology +17

Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019

Silke Gillessen, Gerhardt Attard, Tomasz M. Beer et al. · European Urology · 2020 · 395 citations · Full text

Medicine, Oncology, Urology +17